JiangXi Tianxin Pharmaceutical Co., Ltd. (SHA:603235)
China · Delayed Price · Currency is CNY 25.51
-0.34 (-1.32%)
Oct 27, 2026, 4:00 PM EDT
SHA:603235 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 11,101 | 11,737 | 11,145 | 10,524 | 12,748 | - | |
Market Cap Growth | -6.14% | 5.30% | 5.90% | -17.45% | - | - |
Enterprise Value | 9,895 | 10,583 | 9,508 | 8,230 | 12,181 | - |
Last Close Price | 25.51 | 26.30 | 24.32 | 22.42 | 26.50 | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 20.23 | 19.84 | 17.11 | 22.12 | 20.49 | - |
PS Ratio | 4.30 | 5.01 | 5.05 | 5.59 | 5.53 | - |
PB Ratio | 2.18 | 2.39 | 2.42 | 2.49 | 3.14 | - |
P/TBV Ratio | 2.26 | 2.48 | 2.52 | 2.61 | 3.23 | - |
P/FCF Ratio | 29.10 | 241.09 | - | 54.36 | 36.83 | - |
P/OCF Ratio | 15.69 | 18.65 | 22.31 | 14.43 | 21.02 | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 3.84 | 4.51 | 4.31 | 4.37 | 5.29 | - |
EV/EBITDA Ratio | 12.05 | 12.93 | 12.34 | 15.11 | 17.51 | - |
EV/EBIT Ratio | 16.43 | 16.73 | 15.36 | 20.13 | 21.29 | - |
EV/FCF Ratio | 25.94 | 217.40 | - | 42.51 | 35.19 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.11 | 0.08 | 0.03 | 0.03 | 0.00 | 0.18 |
Debt / EBITDA Ratio | 0.67 | 0.49 | 0.19 | 0.20 | 0.01 | 0.36 |
Debt / FCF Ratio | 1.44 | 8.32 | - | 0.56 | 0.02 | 0.58 |
Net Debt / Equity Ratio | -0.24 | -0.24 | -0.31 | -0.52 | -0.56 | -0.19 |
Net Debt / EBITDA Ratio | -1.48 | -1.42 | -1.83 | -4.04 | -3.29 | -0.38 |
Net Debt / FCF Ratio | -3.16 | -23.93 | 2.49 | -11.36 | -6.62 | -0.61 |
Asset Turnover | 0.42 | 0.40 | 0.41 | 0.39 | 0.60 | 0.86 |
Inventory Turnover | 2.43 | 2.36 | 2.41 | 2.47 | 3.31 | 3.89 |
Quick Ratio | 2.30 | 3.20 | 3.88 | 5.62 | 8.55 | 1.68 |
Current Ratio | 3.15 | 4.38 | 5.29 | 6.77 | 10.18 | 2.33 |
Return on Equity (ROE) | 11.16% | 12.41% | 14.72% | 11.48% | 20.85% | 48.56% |
Return on Assets (ROA) | 6.08% | 6.70% | 7.24% | 5.23% | 9.37% | 18.39% |
Return on Invested Capital (ROIC) | 13.37% | 15.27% | 19.94% | 18.12% | 29.64% | 72.55% |
Return on Capital Employed (ROCE) | 10.90% | 11.40% | 12.20% | 8.80% | 13.10% | 37.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 4.94% | 5.04% | 5.84% | 4.52% | 4.88% | - |
FCF Yield | 3.44% | 0.41% | -5.09% | 1.84% | 2.71% | - |
Dividend Yield | 2.16% | 2.04% | 2.66% | 2.08% | 2.44% | - |
Payout Ratio | 45.11% | 51.53% | 33.81% | 65.66% | 1.10% | 118.09% |
Buyback Yield / Dilution | -0.67% | -0.26% | -0.11% | -5.96% | -4.68% | 0.10% |
Total Shareholder Return | 1.48% | 1.78% | 2.54% | -3.88% | -2.24% | 0.10% |